Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
Four years after which members of the World Trade Organisation ("WTO") agreed upon a system by which developing countries could import generic versions of patented medicines produced without authorisation of patent holders to address public health needs, no country had yet spoken. 1 On July 19, 2007...
| Main Author: | |
|---|---|
| Other Authors: | |
| Format: | Thesis |
| Language: | English English |
| Published: |
Centre for Law and Society
2026
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
| Summary: | Four years after which members of the World Trade Organisation ("WTO") agreed upon a system by which developing countries could import generic versions of patented medicines produced without authorisation of patent holders to address public health needs, no country had yet spoken. 1 On July 19, 2007, Rwanda took a dramatic leap of faith to break the spell of silence and become the first and only country to inform the WTO of its intent to utilise those very procedures. Before Rwanda, no developing country had ever made use of compulsory licensing as a tool to address public health issues. |
|---|